On October 29, 2019 DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, reported that two posters updating results from the company’s two Phase 2 clinical trials of VAL-083 will be presented at the 2019 Society for NeuroOncology Annual meeting in Phoenix, Ariz (Press release, DelMar Pharmaceuticals, OCT 29, 2019, View Source [SID1234549968]). Details regarding the posters are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: "Clinical Trial of VAL-083 in Newly-Diagnosed MGMT-unmethylated GBM: Half-Way Report"
Date/Time: Friday, November 22, 2019, 6:00 PM MT
Lead Author: Dr. Zhong-Ping Chen
This poster will include data from the company’s ongoing Phase 2 trial of VAL-083 being conducted at Sun Yat-sen University Cancer Center as a first line therapy, and includes updates on enrollment, safety and efficacy.

Title: "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting"
Date/Time: Friday, November 22, 2019, 6:00 PM MT
Lead Author: Dr. Barbara O’Brien
This poster will include data from the company’s ongoing Phase 2 trial of VAL-083 being conducted at M.D. Anderson Cancer Center as a treatment in the recurrent and adjuvant settings, and includes updates on enrollment, safety and efficacy.

The 2019 Society for NeuroOncology Annual meeting will be held from November 20-24, 2019 at the JW Marriott Desert Ridge, 5350 E. Marriott Drive in Phoenix, Ariz.